- $19.47m
- $41.54m
- $9.64m
- 26
- 42
- 64
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -68.82% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.4 | 1.42 | 3.38 | 7.65 | 9.64 | 12 | 14.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.
Directors
- Waqaas Al-Siddiq CHM
- John Ayanoglou CFO (51)
- Patricia Kennedy DRC
- Stephen Salmon DRC
- Norman Betts IND
- David Rosa IND
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 29th, 2012
- Public Since
- October 26th, 2015
- No. of Shareholders
- 210
- No. of Employees
- 55
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 11,596,637
- Address
- 203 Redwood Parkway, Suite 600, REDWOOD CITY, 94065
- Web
- https://www.biotricity.com/
- Phone
- +1 6508321626
- Auditors
- SRCO Professional Corporation
Upcoming Events for BTCY
Biotricity Inc Annual Shareholders Meeting
Biotricity Inc Extraordinary Shareholders Meeting
Q1 2025 Biotricity Inc Earnings Release
Q2 2025 Biotricity Inc Earnings Release
Similar to BTCY
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
What is the Biotricity share price?
As of Today at 19:38 UTC, shares in Biotricity are trading at $0.95. This share price information is delayed by 15 minutes.
How has the Biotricity share price performed this year?
Shares in Biotricity last closed at $0.95 and the price had moved by -75.64% over the past 365 days. In terms of relative price strength the Biotricity share price has underperformed the S&P500 Index by -80.62% over the past year.
What are the analyst and broker recommendations for Biotricity?
The overall consensus recommendation for Biotricity is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biotricity dividend yield?
Biotricity does not currently pay a dividend.
Does Biotricity pay a dividend?
Biotricity does not currently pay a dividend.
When does Biotricity next pay dividends?
Biotricity does not currently pay a dividend.
How do I buy Biotricity shares?
To buy shares in Biotricity you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biotricity?
As of the previous close price of $0.95, shares in Biotricity had a market capitalisation of $11.02m.
Where are Biotricity shares listed?
Here are the trading details for Biotricity:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BTCY
What kind of share is Biotricity?
Based on an overall assessment of its quality, value and momentum Biotricity is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biotricity share price forecast for 2024?
The analyst consensus target price for shares in Biotricity is $4.00. That is 321.05% above the last closing price of $0.95.
Analysts covering Biotricity currently have a consensus Earnings Per Share (EPS) forecast of -$1.55 for the next financial year.
What is the trend in the Biotricity share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotricity. Over the past six months, its share price has underperformed the S&P500 Index by -24.54%.
As of the last closing price of $0.95, shares in Biotricity were trading -25.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biotricity PE Ratio?
The Biotricity PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biotricity?
Biotricity's management team is headed by:
- Waqaas Al-Siddiq - CHM
- John Ayanoglou - CFO
- Patricia Kennedy - DRC
- Stephen Salmon - DRC
- Norman Betts - IND
- David Rosa - IND